Market Overview

UPDATE: Morgan Stanley Reiterates on Cherry Hill Mortgage Investment on Better Book Value, Solid Earnings


In a report published Tuesday, Morgan Stanley analyst Cheryl M. Pate reiterated an Equal-Weight rating on Cherry Hill Mortgage Investment (NYSE: CHMI), and raised the price target from $20.00 to $21.00.

In the report, Morgan Stanley noted, “Cherry Hill's reported 50c in core earnings for its first operating quarter, and beat our expectations on solid net interest income. Management remains focused on its excess MSR and agency MSR strategies. In the first quarter, Cherry Hill agreed to purchase ~$76.8m in excess servicing UPB from Freedom Mortgage. While 1Q13TD volumes are light of our prior forecast ($1.4B), the purchases show execution on further excess MSRs and we expect volumes to increase on a go‐forward basis.

"Additionally, management is planning to pursue the appropriate licenses and approvals within its taxable REIT structure to be able to own MSRs outright, a positive in our view.”

Cherry Hill Mortgage Investment closed on Monday at $18.75.

Latest Ratings for CHMI

Sep 2019ReiteratesMarket Outperform
Jun 2018UpgradesNeutralOutperform
Oct 2016Initiates Coverage onNeutral

View More Analyst Ratings for CHMI
View the Latest Analyst Ratings

Posted-In: Cheryl M. Pate Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (CHMI)

View Comments and Join the Discussion!

Latest Ratings

POWLSidoti & Co.Maintains47.0
XDeutsche BankInitiates Coverage On121.0
WTEBMO CapitalMaintains18.0
DOLBMO CapitalMaintains50.0
NABMO CapitalMaintains69.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Morning Market Movers

UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step